<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03429556</url>
  </required_header>
  <id_info>
    <org_study_id>EB001-ABD201</org_study_id>
    <nct_id>NCT03429556</nct_id>
  </id_info>
  <brief_title>Study to Evaluate EB-001 in Reducing Musculoskeletal Pain in Abdominoplasty</brief_title>
  <official_title>A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Intramuscular (IM) Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Abdominoplasty Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bonti, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bonti, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of single intra-operative treatment of EB-001 IM
      injections into the Rectus Abdominus (RA) in subjects undergoing abdominoplasty.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's assessment of pain using the Numeric Pain Rating Scale (NPRS)</measure>
    <time_frame>96 Hours</time_frame>
    <description>Assessment of change in Numeric Pain Rating Scale (values from 0 (best) to 10 (worst)) from completion of surgery to 96 hours after surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Abdominoplasty</condition>
  <arm_group>
    <arm_group_label>EB-001 Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EB-001</intervention_name>
    <description>EB-001 Injection</description>
    <arm_group_label>EB-001 Injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Injection</description>
    <arm_group_label>Placebo Injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women 23 to 55 years of age, inclusive

          2. Men or women who are in good health as determined by medical history, physical
             examination, clinical laboratory studies, ECGs, vital signs, and Investigator judgment

          3. Scheduled to undergo elective abdominoplastry surgery with full length plication from
             xyphoid to pubis, and removal of skin/fat flap under general anesthesia (endotracheal
             or otherwise) without liposuction

          4. American Society of Anesthesiologist (ASA) Physical Class 1-2

          5. Women of non-childbearing potential or postmenopausal (at least 12 consecutive months
             of amenorrhea)

          6. Women of childbearing potential must not be pregnant, lactating, or planning to become
             pregnant during the study

          7. Women of childbearing potential agreeing to use either:

               1. a highly effective method of contraception with failures rates less than 1% per
                  year such as implant, intrauterine device (IUD), or confirmed sterilization and
                  sterilization procedure at least 3 months prior to the day of dosing

               2. dual methods of contraception with overall failures rate less than 1% per year
                  such as injectable, pill, patch, ring, and diaphragm from the day of dosing for 3
                  months (subjects using oral contraception must have initiated treatment at least
                  2 months prior to the day of dosing)

          8. Men with partner(s) of childbearing potential agreeing to use dual methods of
             contraception from the day of dosing until 3 months afterwards, and to no sperm
             donation from day of dosing until 3 months afterwards.

          9. Willing and able to complete protocol requirements and instructions, which includes
             completion of all required visits, procedures and in-clinic stays until the end of the
             study

         10. Willing and able to sign and date IRB-approved informed consent

         11. Able to speak, read, and understand the language of the informed consent form (ICF)
             and study questionnaires

        Exclusion Criteria:

          1. History of prior major abdominal surgery as judged by the investigator

          2. Pre-existing lung disease that could impact subject safety in the opinion of the
             investigator

          3. History of smoking within the past two years

          4. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton-
             Lambert syndrome, or amyotrophic lateral Sclerosis)

          5. Any past or current medical condition that in opinion of investigator, puts subject at
             undue safety risk for surgical complications or for use of the investigational product

          6. At high risk of deep vein thrombosis as judged by the investigators determined by a
             Caprini score of 3 or higher

          7. History of diabetes

          8. Any clinically significant psychiatric condition that, in opinion of investigator, may
             interfere with study assessments or protocol compliance

          9. History of alcohol or drug abuse in the last 3 years, based on investigator judgement

         10. Slow vital capacity that is below 80% of normal value for respective race, age,
             height, and gender or below 2.5 L of absolute volume

         11. Pulse oximetry below 95%

         12. Body weight less than 50 kg (110 pounds) or a Body Mass Index (BMI) of â‰¥ 32

         13. Documented diagnosis of chronic pain condition, or other painful pre-operative
             condition that, in the opinion of the investigator, may require analgesic treatment in
             the post-operative period (e.g. significant joint pain, neuropathic pain)

         14. Known hypersensitivity to any botulinum toxin serotype or to any component of the
             formulation

         15. Reported use of any botulinum toxin within 3 months prior to the date of surgery

         16. Anticipated use of any botulinum toxin of any serotype during the study

         17. Use of long acting opioids within 3 days or any opioid medication within 24 hours
             prior to surgery

         18. Aminoglycoside intake within 48 hours prior to or during surgery

         19. Subjects on anti-depressant or anti-psychotic medications

         20. Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into
             this study

         21. Subject plans to donate blood or plasma from 30 days prior to screening until last
             follow-up visit (Day 29)

         22. Reported pain score of 2 or more at screening on the 11-point scale NPRS-A following
             an activity after and walking approximately 10 feet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wajdie Ahmad</last_name>
    <phone>9493795659</phone>
    <email>wajdie@bonti.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Singla, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain, neurotoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

